Explore the platform for protein and drug discovery. Innophore is a cutting-edge drug and enzyme discovery platform that uses an artificial intelligence guided point-cloud technology to identify and optimize protein candidates for various use cases. We have leading global customers in the biotech and pharmaceutical industry, including Henkel, Continental, Merck and leading companies in the field of flavours and fragrances. Our AI-driven platform, fueled by massive computing power, not only analyzes a protein’s 3D structure, but includes extended surface properties (HALOS) and volumetric cavities (catalophores), to predict its characteristics and reactivity. This puts our customers at the forefront of tackling problems in drug discovery/repurposing and opens new ways in the sustainable production of high-value compounds. Accelerate your R&D pipeline. Over the course of 20 years, protein structure database entries have grown from 13,587 to nearly a billion. This includes a recently published breakthrough database from DeepMind and the ESM Metagenomic Atlas. It is easy to get lost in the vast amount of bioinformatics information available to us today. To identify new drug candidates or enzymes based on this vast amount of data, we need to change the way we search and go beyond traditional algorithms and data types. By integrating our patented CatalophoreTM technology with a state-of-the-art conventional bioinformatics approach, as well as artificial intelligence, we are able to mine structural and sequence databases using three-dimensional (3D) search templates called “catalophores” (i.e., carrier of the catalytic function) defined by point clouds of physicochemical features. Our CatalophoreTM platform improves your wet-lab performance by minimizing the volume of in-vitro screening experiments. Our in-silico approach significantly decreases time to market and increases the probability of your success.